Stifel on Structure Therapeutics (GPCR): ACCESS-II data supports 'low and slow' strategy ahead of Ph3
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $90.00 price target on Structure Therapeutics (NASDAQ: GPCR)The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
